BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/15/2022 7:06:22 AM | Browse: 403 | Download: 672
 |
Received |
|
2021-05-31 14:44 |
|
Peer-Review Started |
|
2021-05-31 14:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-31 04:32 |
|
Revised |
|
2021-08-13 07:32 |
|
Second Decision |
|
2022-01-04 03:26 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-01-05 02:56 |
|
Articles in Press |
|
2022-01-05 02:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-07 03:55 |
|
Publish the Manuscript Online |
|
2022-01-15 07:06 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Chronic hepatitis B: New potential therapeutic drugs target
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana and Tawithep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, MD, MSc, PhD, Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6
rajavithi road, rachatawee, Bangkok 10400, Thailand, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Chronic hepatitis B; Hepatitis B surface antigen; Hepatitis B surface antibody; Covalently closed circular DNA; Direct acting antiviral drugs; Functional cure; Entry block; Nucleocapsid assembly modulator; Interfering hepatitis B virus transcription; Inhibiting hepatitis B surface antigen release |
| Core Tip |
Current treatment of chronic hepatitis B infection with nucleos(t)ide analogs causes long-term suppression of hepatitis B virus (HBV) DNA levels, significantly improving hepatocellular injury and extrahepatic complications. However, the risk of hepatocellular carcinoma remains increased. New direct antiviral drugs that target the HBV life cycle, including entry blockers, assembly modulators, covalently closed circular DNA (cccDNA) disruptors, and hepatitis B surface antigen release inhibitors, would lead to hepatitis B surface antigen loss and a functional cure. Moreover, a combination of antiviral drugs with an immune-modulator could enhance the elimination of cccDNA and provide a definitive cure. |
| Publish Date |
2022-01-15 07:06 |
| Citation |
Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol 2022; 11(1): 57-72 |
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i1/57.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i1.57 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
